Nutritional status alterations after chimeric antigen receptor T cell therapy in patients with hematological malignancies: a retrospective study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34988704/
The alterations of different nutrition-related biochemical parameters varied after CAR-T cell therapy. The levels of albumin and total cholesterol after CAR-T cell infusion were negatively correlated with the grade of...
Conclusion: The alterations of different nutrition-related biochemical parameters varied after CAR-T cell therapy. The levels of albumin and total cholesterol after CAR-T cell infusion were negatively correlated with the grade of cytokine release syndrome. Specific screening and intervention for malnutrition in patients receiving CAR-T cell...
The role of KIAA1191 in the necroptotic pathway of multiple myeloma - Annals of Hematology
Source : https://link.springer.com/article/10.1007/s00277-021-04710-w
Multiple myeloma (MM) is an incurable plasma cell malignancy, and International Staging System (ISS) is used to predict the outcomes of MM patients. However, ISS stage is imperfect, and there...
Conclusion/Relevance: We found that KIAA1191 was associated with both overall survival and progression-free survival of MM patients. Furthermore, KIAA1191 high expression suppressed the proliferation and migration of MM cells; upregulated the expression of RIP1, RIP3, and CYLD, and restored the TNF-α/z-VAD-induced necroptosis. Besides,...
Daratumumab for the Treatment of Multiple Myeloma: A Review of Clinical Applicability and Operational Considerations - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34963325/
doi: 10.1177/10600280211058754. Online ahead of print. 1 Specialty Pharmacy Service, Atrium Health, Charlotte, NC, USA. 2 Department of Pharmaceutical Services, Winship Cancer Institute, Emory University Hospitals, Atlanta, GA, USA. 3...
Conclusions: Daratumumab has led to a shift in the treatment paradigm of both newly diagnosed and relapsed/refractory MM, leading to improvements in outcomes such as response rates, depth of response, and progression-free survival.
Belantamab mafodotin for the treatment of multiple myeloma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34821879/
Multiple myeloma is the second most common hematologic malignancy worldwide. Despite the growing number of available therapeutic options and advances in the treatment since the 2000s, relapse of multiple myeloma...
Conclusion/Relevance: Although belantamab mafodotin has demonstrated single-agent activity in relapsed/refractory multiple myeloma, further studies to evaluate its efficacy and its combinational use with other drugs are necessary and ongoing.
"Real-life" data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experience - Blood Cancer Journal
Source : https://www.nature.com/articles/s41408-021-00592-3
Belantamab mafodotin is a highly selective targeted therapy for multiple myeloma. It targets the B cell maturation antigen (BCMA) on plasma cells and showed promising results in several randomized clinical...
Conclusion/Relevance: In conclusion, the results of “real life” belantamab are similar to those published in the RCTs, and despite some promise, the role of belantamab in the era of other BCMA directed therapy (CAR-T, bispecific T cell engagers) remains unclear.